



Viral Genetics Webcast Conference Call on Core Strategic Developments

SOURCE: Viral Genetics, Inc.

Viral Genetics Webcast Conference Call on Core Strategic Developments, Viral Genetics, Inc. (Pinksheets:VRAL.pk) is hosting a webcast conference call this coming Wednesday, August 3, 2011 to provide updates on the company's core strategic elements

Business Wire

SAN MARINO, Calif., Aug. 1, 2011 /PRNewswire/ — Viral Genetics, Inc. (Pinksheets:VRAL.pk – News) is hosting a webcast conference call this coming Wednesday, August 3, 2011 to provide updates on the company's core strategic elements. Among the topics to be discussed are: status of Clinical Trial at Scott & White Medical, progress at VG Energy regarding the demonstration of industrial scale production of enhanced algal bio-fuel, and details on the IND for HIV/AIDS and Lyme disease.

The conference call begins at 1:30 pm Pacific / 4:30 pm Eastern on Wednesday, August 3, 2011. To sign on to the webcast, follow this link: <http://www.visualwebcaster.com/event.asp?id=81009>. The very simple registration process takes less than 10 seconds and can be undertaken anytime prior to the webcast.

Haig Keledjian, Viral Genetics' CEO, said, "This conference call marks a turning point in the evolution of our investor outreach communications. The brilliance of our Chief Scientific Advisor, Dr. Karen Newell-Rogers, has created a core science platform for the company that allows us to derive value from a multitude of high-growth business opportunities, and we are advancing on these opportunities daily. We look forward to bringing all of our shareholders and potential investors up to date on our progress and most importantly provide an understanding of our growth path in the near future."

About Viral Genetics, Inc.

San Marino, California-based Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. For more information, visit www.viralgenetics.com. About VG Energy VG Energy Inc. is an alternative energy and agricultural biotech company that is a majority-owned subsidiary of Viral Genetics Inc. Using its Metabolic Disruption Technology (MDT), Viral Genetics' cancer research led to discoveries with major consequences in a wide variety of other industries, including production of biofuel and vegetable oils. VG Energy holds the exclusive worldwide license to the MDT patent rights for use in the increase of production of various plant-derived oils from algae and seeds. Application of MDT technology to the biofuel industry could potentially allow it to overcome its major obstacle in the area of production efficiency: namely, an increase in production yields leading to feasible economic returns on investment, allowing renewable biodiesel to be competitive with fossil fuels. For more information, please visit www.vgenergy.net.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports, including statements about its VG Energy, Inc. subsidiary. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized.

While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.'s non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

Contact:

Viral Genetics, Inc.

Haig Keledjian, 626-334-5310

